DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Midostaurin |
DMI6E0R
|
Moderate |
Increased metabolism of Cenobamate caused by Midostaurin mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[5] |
Gilteritinib |
DMTI0ZO
|
Moderate |
Increased metabolism of Cenobamate caused by Gilteritinib mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[6] |
Oliceridine |
DM6MDCF
|
Major |
Increased metabolism of Cenobamate caused by Oliceridine mediated induction of CYP450 enzyme. |
Acute pain [MG31]
|
[7] |
Ivabradine |
DM0L594
|
Moderate |
Increased metabolism of Cenobamate caused by Ivabradine mediated induction of CYP450 enzyme. |
Angina pectoris [BA40]
|
[8] |
Bedaquiline |
DM3906J
|
Major |
Increased metabolism of Cenobamate caused by Bedaquiline mediated induction of CYP450 enzyme. |
Antimicrobial drug resistance [MG50-MG52]
|
[8] |
Erdafitinib |
DMI782S
|
Major |
Increased metabolism of Cenobamate caused by Erdafitinib mediated induction of CYP450 enzyme. |
Bladder cancer [2C94]
|
[9] |
Pexidartinib |
DMS2J0Z
|
Moderate |
Increased metabolism of Cenobamate caused by Pexidartinib mediated induction of CYP450 enzyme. |
Bone/articular cartilage neoplasm [2F7B]
|
[10] |
HKI-272 |
DM6QOVN
|
Major |
Increased metabolism of Cenobamate caused by HKI-272 mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[11] |
LY2835219 |
DM93VBZ
|
Moderate |
Increased metabolism of Cenobamate caused by LY2835219 mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[12] |
Esterified estrogens |
DM9KZDO
|
Moderate |
Increased metabolism of Cenobamate caused by Esterified estrogens mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[13] |
Tucatinib |
DMBESUA
|
Moderate |
Increased metabolism of Cenobamate caused by Tucatinib mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[14] |
Palbociclib |
DMD7L94
|
Moderate |
Increased metabolism of Cenobamate caused by Palbociclib mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[11] |
Alpelisib |
DMEXMYK
|
Moderate |
Increased metabolism of Cenobamate caused by Alpelisib mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[15] |
Cabazitaxel |
DMPAZHC
|
Moderate |
Increased metabolism of Cenobamate caused by Cabazitaxel mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[16] |
Bosutinib |
DMTI8YE
|
Major |
Increased metabolism of Cenobamate caused by Bosutinib mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[17] |
Macitentan |
DMP79A1
|
Moderate |
Increased metabolism of Cenobamate caused by Macitentan mediated induction of CYP450 enzyme. |
Cardiovascular disease [BA00-BE2Z]
|
[18] |
PF-04449913 |
DMSB068
|
Major |
Increased metabolism of Cenobamate caused by PF-04449913 mediated induction of CYP450 enzyme. |
Chronic myelomonocytic leukaemia [2A40]
|
[19] |
Intedanib |
DMSTA36
|
Moderate |
Increased metabolism of Cenobamate caused by Intedanib mediated induction of CYP450 enzyme. |
Colorectal cancer [2B91]
|
[20] |
Levonorgestrel |
DM1DP7T
|
Moderate |
Increased metabolism of Cenobamate caused by Levonorgestrel mediated induction of CYP450 enzyme. |
Contraceptive management [QA21]
|
[13] |
Osilodrostat |
DMIJC9X
|
Moderate |
Increased metabolism of Cenobamate caused by Osilodrostat mediated induction of CYP450 enzyme. |
Cushing syndrome [5A70]
|
[21] |
Ivacaftor |
DMZC1HS
|
Moderate |
Increased metabolism of Cenobamate caused by Ivacaftor mediated induction of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[22] |
Rivaroxaban |
DMQMBZ1
|
Moderate |
Increased metabolism of Cenobamate caused by Rivaroxaban mediated induction of CYP450 enzyme. |
Deep vein thrombosis [BD71]
|
[23] |
Vilazodone |
DM4LECQ
|
Moderate |
Increased metabolism of Cenobamate caused by Vilazodone mediated induction of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[24] |
Vortioxetine |
DM6F1PU
|
Moderate |
Increased metabolism of Cenobamate caused by Vortioxetine mediated induction of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[25] |
OPC-34712 |
DMHG57U
|
Moderate |
Increased metabolism of Cenobamate caused by OPC-34712 mediated induction of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[20] |
Esketamine |
DMVU687
|
Moderate |
Additive CNS depression effects by the combination of Cenobamate and Esketamine. |
Depression [6A70-6A7Z]
|
[11] |
Polatuzumab vedotin |
DMF6Y0L
|
Moderate |
Increased metabolism of Cenobamate caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. |
Diffuse large B-cell lymphoma [2A81]
|
[20] |
Cannabidiol |
DM0659E
|
Moderate |
Increased metabolism of Cenobamate caused by Cannabidiol mediated induction of CYP450 enzyme. |
Epileptic encephalopathy [8A62]
|
[20] |
Bay 80-6946 |
DMLOS5R
|
Moderate |
Increased metabolism of Cenobamate caused by Bay 80-6946 mediated induction of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[26] |
Tazemetostat |
DMWP1BH
|
Major |
Increased metabolism of Cenobamate caused by Tazemetostat mediated induction of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[27] |
Mirabegron |
DMS1GYT
|
Minor |
Increased metabolism of Cenobamate caused by Mirabegron mediated induction of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[28] |
Ripretinib |
DM958QB
|
Moderate |
Increased metabolism of Cenobamate caused by Ripretinib mediated induction of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[11] |
Avapritinib |
DMK2GZX
|
Major |
Increased metabolism of Cenobamate caused by Avapritinib mediated induction of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[8] |
Boceprevir |
DMBSHMF
|
Moderate |
Increased metabolism of Cenobamate caused by Boceprevir mediated induction of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[29] |
Daclatasvir |
DMSFK9V
|
Major |
Increased metabolism of Cenobamate caused by Daclatasvir mediated induction of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[8] |
MK-1439 |
DM215WE
|
Major |
Increased metabolism of Cenobamate caused by MK-1439 mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[8] |
Fostemsavir |
DM50ILT
|
Minor |
Increased metabolism of Cenobamate caused by Fostemsavir mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[30] |
Cobicistat |
DM6L4H2
|
Moderate |
Increased metabolism of Cenobamate caused by Cobicistat mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[7] |
Dolutegravir |
DMCZGRE
|
Minor |
Increased metabolism of Cenobamate caused by Dolutegravir mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[31] |
Elvitegravir |
DMG9B1U
|
Moderate |
Increased metabolism of Cenobamate caused by Elvitegravir mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[11] |
Etravirine |
DMGV8QU
|
Moderate |
Decreased metabolism of Cenobamate caused by Etravirine mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[32] |
Rilpivirine |
DMJ0QOW
|
Moderate |
Increased metabolism of Cenobamate caused by Rilpivirine mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[11] |
Tolvaptan |
DMIWFRL
|
Moderate |
Increased metabolism of Cenobamate caused by Tolvaptan mediated induction of CYP450 enzyme. |
Hypo-osmolality/hyponatraemia [5C72]
|
[8] |
Suvorexant |
DM0E6S3
|
Moderate |
Increased metabolism of Cenobamate caused by Suvorexant mediated induction of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[33] |
Tasimelteon |
DMLOQ1V
|
Moderate |
Increased metabolism of Cenobamate caused by Tasimelteon mediated induction of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[34] |
Naloxegol |
DML0B41
|
Moderate |
Increased metabolism of Cenobamate caused by Naloxegol mediated induction of CYP450 enzyme. |
Large intestine motility disorder [DB32]
|
[35] |
Pemigatinib |
DM819JF
|
Major |
Increased metabolism of Cenobamate caused by Pemigatinib mediated induction of CYP450 enzyme. |
Liver cancer [2C12]
|
[8] |
Crizotinib |
DM4F29C
|
Moderate |
Increased metabolism of Cenobamate caused by Crizotinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[36] |
Brigatinib |
DM7W94S
|
Major |
Increased metabolism of Cenobamate caused by Brigatinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[11] |
Ceritinib |
DMB920Z
|
Moderate |
Increased metabolism of Cenobamate caused by Ceritinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[37] |
Lurbinectedin |
DMEFRTZ
|
Major |
Decreased metabolism of Cenobamate caused by Lurbinectedin mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[38] |
PF-06463922 |
DMKM7EW
|
Major |
Increased metabolism of Cenobamate caused by PF-06463922 mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[39] |
Osimertinib |
DMRJLAT
|
Moderate |
Increased metabolism of Cenobamate caused by Osimertinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[40] |
Pralsetinib |
DMWU0I2
|
Moderate |
Increased metabolism of Cenobamate caused by Pralsetinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[41] |
Selpercatinib |
DMZR15V
|
Major |
Increased metabolism of Cenobamate caused by Selpercatinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[8] |
Artemether |
DM48QOT
|
Moderate |
Increased metabolism of Cenobamate caused by Artemether mediated induction of CYP450 enzyme. |
Malaria [1F40-1F45]
|
[11] |
Idelalisib |
DM602WT
|
Moderate |
Increased metabolism of Cenobamate caused by Idelalisib mediated induction of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[42] |
GDC-0199 |
DMH0QKA
|
Major |
Increased metabolism of Cenobamate caused by GDC-0199 mediated induction of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[43] |
IPI-145 |
DMWA24P
|
Moderate |
Increased metabolism of Cenobamate caused by IPI-145 mediated induction of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[44] |
Acalabrutinib |
DM7GCVW
|
Moderate |
Increased metabolism of Cenobamate caused by Acalabrutinib mediated induction of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[45] |
Ibrutinib |
DMHZCPO
|
Moderate |
Increased metabolism of Cenobamate caused by Ibrutinib mediated induction of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[46] |
Ponatinib |
DMYGJQO
|
Moderate |
Increased metabolism of Cenobamate caused by Ponatinib mediated induction of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[11] |
Vemurafenib |
DM62UG5
|
Moderate |
Increased metabolism of Cenobamate caused by Vemurafenib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[47] |
Selumetinib |
DMC7W6R
|
Major |
Increased metabolism of Cenobamate caused by Selumetinib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[48] |
LGX818 |
DMNQXV8
|
Major |
Increased metabolism of Cenobamate caused by LGX818 mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[49] |
Allopregnanolone |
DMNLHAC
|
Moderate |
Additive CNS depression effects by the combination of Cenobamate and Allopregnanolone. |
Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]
|
[50] |
Ubrogepant |
DM749I3
|
Moderate |
Increased metabolism of Cenobamate caused by Ubrogepant mediated induction of CYP450 enzyme. |
Migraine [8A80]
|
[51] |
Rimegepant |
DMHOAUG
|
Major |
Increased metabolism of Cenobamate caused by Rimegepant mediated induction of CYP450 enzyme. |
Migraine [8A80]
|
[52] |
Lasmiditan |
DMXLVDT
|
Moderate |
Additive CNS depression effects by the combination of Cenobamate and Lasmiditan. |
Migraine [8A80]
|
[53] |
Panobinostat |
DM58WKG
|
Moderate |
Increased metabolism of Cenobamate caused by Panobinostat mediated induction of CYP450 enzyme. |
Multiple myeloma [2A83]
|
[54] |
Siponimod |
DM2R86O
|
Major |
Increased metabolism of Cenobamate caused by Siponimod mediated induction of CYP450 enzyme. |
Multiple sclerosis [8A40]
|
[11] |
Deflazacort |
DMV0RNS
|
Major |
Increased metabolism of Cenobamate caused by Deflazacort mediated induction of CYP450 enzyme. |
Muscular dystrophy [8C70]
|
[8] |
Romidepsin |
DMT5GNL
|
Moderate |
Increased metabolism of Cenobamate caused by Romidepsin mediated induction of CYP450 enzyme. |
Mycosis fungoides [2B01]
|
[20] |
Fedratinib |
DM4ZBK6
|
Major |
Increased metabolism of Cenobamate caused by Fedratinib mediated induction of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[8] |
Ruxolitinib |
DM7Q98D
|
Moderate |
Increased metabolism of Cenobamate caused by Ruxolitinib mediated induction of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[55] |
Rolapitant |
DM8XP26
|
Moderate |
Increased metabolism of Cenobamate caused by Rolapitant mediated induction of CYP450 enzyme. |
Nausea/vomiting [MD90]
|
[56] |
Entrectinib |
DMMPTLH
|
Major |
Increased metabolism of Cenobamate caused by Entrectinib mediated induction of CYP450 enzyme. |
Non-small cell lung cancer [2C25]
|
[57] |
S-297995 |
DM26IH8
|
Moderate |
Increased metabolism of Cenobamate caused by S-297995 mediated induction of CYP450 enzyme. |
Opioid use disorder [6C43]
|
[8] |
Olaparib |
DM8QB1D
|
Major |
Increased metabolism of Cenobamate caused by Olaparib mediated induction of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[11] |
Istradefylline |
DM20VSK
|
Moderate |
Increased metabolism of Cenobamate caused by Istradefylline mediated induction of CYP450 enzyme. |
Parkinsonism [8A00]
|
[58] |
Macimorelin |
DMQYJIR
|
Moderate |
Increased metabolism of Cenobamate caused by Macimorelin mediated induction of CYP450 enzyme. |
Pituitary gland disorder [5A60-5A61]
|
[59] |
Lefamulin |
DME6G97
|
Major |
Increased metabolism of Cenobamate caused by Lefamulin mediated induction of CYP450 enzyme. |
Pneumonia [CA40]
|
[60] |
Lonafarnib |
DMGM2Z6
|
Major |
Increased metabolism of Cenobamate caused by Lonafarnib mediated induction of CYP450 enzyme. |
Premature ageing appearance [LD2B]
|
[61] |
Enzalutamide |
DMGL19D
|
Moderate |
Increased metabolism of Cenobamate caused by Enzalutamide mediated induction of CYP450 enzyme. |
Prostate cancer [2C82]
|
[62] |
Darolutamide |
DMV7YFT
|
Moderate |
Increased metabolism of Cenobamate caused by Darolutamide mediated induction of CYP450 enzyme. |
Prostate cancer [2C82]
|
[63] |
Silodosin |
DMJSBT6
|
Moderate |
Increased metabolism of Cenobamate caused by Silodosin mediated induction of CYP450 enzyme. |
Prostate hyperplasia [GA90]
|
[11] |
Riociguat |
DMXBLMP
|
Moderate |
Increased metabolism of Cenobamate caused by Riociguat mediated induction of CYP450 enzyme. |
Pulmonary hypertension [BB01]
|
[64] |
Axitinib |
DMGVH6N
|
Major |
Increased metabolism of Cenobamate caused by Axitinib mediated induction of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[65] |
Temsirolimus |
DMS104F
|
Moderate |
Increased metabolism of Cenobamate caused by Temsirolimus mediated induction of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[11] |
Upadacitinib |
DM32B5U
|
Moderate |
Increased metabolism of Cenobamate caused by Upadacitinib mediated induction of CYP450 enzyme. |
Rheumatoid arthritis [FA20]
|
[66] |
Tofacitinib |
DMBS370
|
Moderate |
Increased metabolism of Cenobamate caused by Tofacitinib mediated induction of CYP450 enzyme. |
Rheumatoid arthritis [FA20]
|
[11] |
Asenapine |
DMSQZE2
|
Moderate |
Increased metabolism of Cenobamate caused by Asenapine mediated induction of CYP450 enzyme. |
Schizophrenia [6A20]
|
[20] |
Avanafil |
DM75CXN
|
Moderate |
Increased metabolism of Cenobamate caused by Avanafil mediated induction of CYP450 enzyme. |
Sexual dysfunction [HA00-HA01]
|
[67] |
Voxelotor |
DMCS6M5
|
Major |
Increased metabolism of Cenobamate caused by Voxelotor mediated induction of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[68] |
LDE225 |
DMM9F25
|
Major |
Increased metabolism of Cenobamate caused by LDE225 mediated induction of CYP450 enzyme. |
Skin cancer [2C30-2C37]
|
[69] |
Larotrectinib |
DM26CQR
|
Moderate |
Increased metabolism of Cenobamate caused by Larotrectinib mediated induction of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[11] |
Armodafinil |
DMGB035
|
Moderate |
Increased metabolism of Cenobamate caused by Armodafinil mediated induction of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[70] |
LEE011 |
DMMX75K
|
Moderate |
Increased metabolism of Cenobamate caused by LEE011 mediated induction of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[11] |
Pitolisant |
DM8RFNJ
|
Moderate |
Increased metabolism of Cenobamate caused by Pitolisant mediated induction of CYP450 enzyme. |
Somnolence [MG42]
|
[20] |
Pomalidomide |
DMTGBAX
|
Moderate |
Increased metabolism of Cenobamate caused by Pomalidomide mediated induction of CYP450 enzyme. |
Systemic sclerosis [4A42]
|
[20] |
Fostamatinib |
DM6AUHV
|
Moderate |
Increased metabolism of Cenobamate caused by Fostamatinib mediated induction of CYP450 enzyme. |
Thrombocytopenia [3B64]
|
[71] |
Apixaban |
DM89JLN
|
Moderate |
Increased metabolism of Cenobamate caused by Apixaban mediated induction of CYP450 enzyme. |
Thrombosis [DB61-GB90]
|
[72] |
Brilinta |
DMBR01X
|
Moderate |
Increased metabolism of Cenobamate caused by Brilinta mediated induction of CYP450 enzyme. |
Thrombosis [DB61-GB90]
|
[7] |
Cabozantinib |
DMIYDT4
|
Moderate |
Increased metabolism of Cenobamate caused by Cabozantinib mediated induction of CYP450 enzyme. |
Thyroid cancer [2D10]
|
[73] |
Saxagliptin |
DMGXENV
|
Moderate |
Increased metabolism of Cenobamate caused by Saxagliptin mediated induction of CYP450 enzyme. |
Type 2 diabetes mellitus [5A11]
|
[74] |
Linagliptin |
DMWFJTR
|
Moderate |
Increased metabolism of Cenobamate caused by Linagliptin mediated induction of CYP450 enzyme. |
Type 2 diabetes mellitus [5A11]
|
[75] |
Elagolix |
DMB2C0E
|
Moderate |
Increased metabolism of Cenobamate caused by Elagolix mediated induction of CYP450 enzyme. |
Uterine fibroid [2E86]
|
[76] |
----------- |
|
|
|
|
|